Viking Therapeutics Inc [VKTX] Is Currently 2.75 below its 200 Period Moving Avg: What Does This Mean?

MDB

Viking Therapeutics Inc [NASDAQ: VKTX] surged by $1.43 during the normal trading session on while it closed the day at $53.42.

Viking Therapeutics Inc stock has also gained 3.71% of its value over the past 7 days. However, VKTX stock has declined by -12.66% in the 3 months of the year. Over the past six months meanwhile, it has lost -16.28% and gained 187.05% year-on date.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The market cap for VKTX stock reached $5.95 billion, with 111.44 million shares outstanding and 108.05 million shares in the current float. Compared to the average trading volume of 4.11M shares, VKTX reached a trading volume of 5173903 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Viking Therapeutics Inc [VKTX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VKTX shares is $112.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VKTX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

B. Riley Securities have made an estimate for Viking Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 22, 2024. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $90 to $102. The new note on the price target was released on November 04, 2024, representing the official price target for Viking Therapeutics Inc stock. Previously, the target price had yet another raise to $80, while JP Morgan analysts kept a Overweight rating on VKTX stock.

The Average True Range (ATR) for Viking Therapeutics Inc is set at 4.27 The Price to Book ratio for the last quarter was 6.53, with the Price to Cash per share for the same quarter was set at 8.35.

VKTX stock trade performance evaluation

Viking Therapeutics Inc [VKTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.71. With this latest performance, VKTX shares dropped by -28.31% in over the last four-week period, additionally sinking by -16.28% over the last 6 months – not to mention a rise of 345.17% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VKTX stock in for the last two-week period is set at 39.74, with the RSI for the last a single of trading hit 39.21, and the three-weeks RSI is set at 41.70 for Viking Therapeutics Inc [VKTX]. The present Moving Average for the last 50 days of trading for this stock 63.24, while it was recorded at 52.23 for the last single week of trading, and 62.61 for the last 200 days.

Viking Therapeutics Inc [VKTX]: An insightful look at the core fundamentals

Viking Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 36.47 and a Current Ratio set at 36.47.

Earnings per share (EPS) analysis for Viking Therapeutics Inc [VKTX] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VKTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Viking Therapeutics Inc go to 40.00%.

Viking Therapeutics Inc [VKTX]: Institutional Ownership

There are presently around $75.48%, or 80.27%% of VKTX stock, in the hands of institutional investors. The top three institutional holders of VKTX stocks are: FMR LLC with ownership of 16.54 million shares, which is approximately 15.9876%. VANGUARD GROUP INC, holding 10.1 million shares of the stock with an approximate value of $$535.26 million in VKTX stocks shares; and VANGUARD GROUP INC, currently with $$319.45 million in VKTX stock with ownership which is approximately 5.8248%.